-
The fixed asset investment of pharmaceutical companies continues to grow, and the upstream industry is expected to enter a period of long-term steady growth
Time of Update: 2021-11-15
The industry believes that with the continued increase in fixed asset investment by pharmaceutical companies, the pharmaceutical equipment industry is expected to transform from short-term explosive growth to long-term steady growth .
-
The new mechanism of antihypertensive drug ARNI is here
Time of Update: 2021-11-15
*Only for medical professionals to read for reference to prevent and control stroke, blood pressure is the last word, the new mechanism of blood pressure drug ARNI is here!
How will the launch of new antihypertensive drugs change clinical practice?
-
Express the prevention and treatment of COVID-19, and the neutralizing antibody combination obtains FDA priority review qualification
Time of Update: 2021-10-21
▎Editor of WuXi AppTec's content team On October 14, 2021, Regeneron announced that the US FDA has granted priority review of a biological product license application (BLA) for its neutralizing antibody combination therapy REGEN-COV (casirivimab+imdevimab) Eligible for the treatment of non-hospitalized COVID-19 patients and as a post-exposure prophylaxis therapy for high-risk populations .
-
The dawn of a complete cure for AIDS: FDA approves the first clinical trial of CRISPR gene editing to treat AIDS in humans
Time of Update: 2021-10-01
Recently, Excision BioTherapeutics announced that its therapy EBT-101 based on CRISPR gene editing technology has been approved by the US FDA and will begin human clinical trials for the treatment of AIDS .
-
Effective for a variety of new crown variants
Time of Update: 2021-08-15
Using cryo-electron microscopy, the researchers analyzed the complex structures of eight highly effective neutralizing nanobodies that bind to the spike protein or RBD .
The second type of nanobody (including Nb34/Nb95/Nb105) binds to the conserved regions of coronaviruses (such as SARS virus and new coronavirus) and can efficiently neutralize multiple mutant strains .
-
Conba's wholly-owned subsidiary methylcobalamin tablets passed the consistency evaluation of generic drugs
Time of Update: 2021-08-04
As of the disclosure date of this announcement, four manufacturers of methylcobalamin tablets that have passed the consistency evaluation of the State Food and Drug Administration include Hangzhou Kangenbei and other four companies .
-
Sansheng Guojian declares the second domestic paragraph of HER2/PD-1 double antibody
Time of Update: 2021-07-30
Currently, immune checkpoint blocking therapies, including anti-PD-1/PD-L1 antibodies, have shown significant clinical benefits in a variety of cancers, but their effectiveness is usually limited to 20%-30% of patients , And most patients develop resistance to treatment over time .
-
BMS withdraws approval of Opdivo monotherapy for Nexavar treatment failure liver cancer indication
Time of Update: 2021-07-30
CompilationTom LeeA few days ago, Bristol-Myers Squibb stated that it would voluntarily withdraw Opdivo's indication approval for hepatocellular carcinoma patients who have previously received Nexavar treatment and have failed the treatment .
-
Enhua Pharmaceutical: Obtained "Drug Registration Certificate" for 3 specifications of Oxycodone Hydrochloride Injection
Time of Update: 2021-07-25
On February 25, Enhua Pharmaceuticals announced that the company has recently obtained the "Drug Registration Certificate" for 3 specifications of oxycodone hydrochloride injection, which is a controlled drug of hemp Jing, approved and issued by the National Medical Products Administration .
-
Jingfeng Pharmaceutical Letrozole Tablets Obtained Drug Registration Approval
Time of Update: 2021-06-22
It is reported that letrozole is a selective, non-steroidal aromatase inhibitor, which has no negative effects on the secretion of glucocorticoids and mineralocorticoids and thyroid function .
It is also suitable for the treatment of postmenopausal, estrogen receptor-positive, progesterone-receptor-positive, or advanced breast cancer patients whose receptor status is unknown.
-
Express | Subcutaneous RNAi Therapy Reached All Phase 3 Clinical Endpoints, New Drug Application Has Been Submitted
Time of Update: 2021-05-10
▎The content team editor of WuXi AppTec today, Alnylam Pharmaceuticals announced that the subcutaneous RNAi therapy vutrisiran developed by the company has reached the primary end point and all the secondary clinical trials in a phase 3 clinical trial for the treatment of patients with hereditary transthyretin (hATTR) amyloidosis.
-
Dongyang Pharmaceutical Group 1 new drugs are coming, 8 innovative drugs hit hard
Time of Update: 2021-05-02
Recently, the CDE official website showed that Dongyang Pharmaceutical’s Class 1 new drug HEC88473 injection and Class 2 new drug Lurasidone delayed-release tablets have been approved for clinical use.
-
Yiling Pharmaceutical's Aniprofen Injection Formally Started Phase III Clinical Trial
Time of Update: 2021-04-18
On April 13, Yiling Pharmaceutical issued an announcement that the company's Phase III clinical trial plan for the company's 1.
From April 2019 to June 2020, the Phase II clinical trial was completed in 8 centers including the Third Xiangya Hospital of Central South University.
-
The first domestic innovative preparation of ropivacaine multivesicular liposome is about to enter the clinic
Time of Update: 2021-03-25
Luye Pharmaceutical Group announced that the clinical trial application of its independently developed innovative preparation-Ropivacaine Hydrochloride Liposome Suspension Injection (LY09606) has been accepted by the Drug Evaluation Center of the National Medical Products Administration and will soon enter the clinical stage .
-
A minimum penalty of 100,000! The most severe penalties for pharmacies are coming
Time of Update: 2021-03-11
4, the minimum penalty of 100,000 illegal acts: according to the new version of the Drug Administration Law, retail pharmacies selling inferior drugs, etc., the value of the drug sold is more than ten times the value of the fine of less than 20 times; same time, the sale of Chinese medicine tablets do not meet the drug standards, has not affected the safety and effectiveness, can be fined between 100,000 yuan and 500,000 yuan.
